CINCINNATI, Jan 10 (Bernama-GLOBE NEWSWIRE) -- Bioline, The PCR Company, a wholly-owned subsidiary of
Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced the expansion of the
EPIK™ miRNA Select Assays, originally developed for the study of individual
microRNA (miRNA) molecules. In collaboration with MiRXES, Bioline released 800
EPIK™ miRNA Select Assays in March 2016 and this has now been increased to
include all of the organisms listed on the miRBase release 21, which represents
over 27,000 miRNA assays. Recent studies continue to show the clinical value of
individual miRNA molecules which are released from tissues and cells. The
expression of certain individual miRNA molecules correlates with specific
disease conditions making them promising biomarker candidates for the early
detection of disease, prognosis and monitoring of treatment in both humans and
other organisms.
No comments:
Post a Comment